Introduction
Colorectal cancer ranks as the third most prevalent malignancy worldwide, with an estimated 1.93 million new cases and 903,859 deaths reported annually.1 Colonoscopy is the gold standard for screening and diagnosis, offering critical benefits in reducing incidence and mortality through early detection and intervention.2 The United States Preventive Services Task Force recommends colorectal cancer screening in adults aged 45 to 49 years.3 However, patient anxiety about procedural discomfort often impedes adherence to these guidelines, significantly contributing to low compliance rates.4 This challenge has led to increased adoption of sedation protocols to enhance patient experience and improve screening adherence.5
Propofol, widely used for colonoscopy sedation due to its rapid onset and short duration,…